Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

• Status: Not yet recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Antimicrobial resistance is a major threat worldwide and now concerns last-ressource antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their use, their spare has become a public health emergency. Their efficacy in ventilator-associated pneumonia has never been compared to other classes of antibiotics such as piperacillin-tazobactam which can be an alternative to carbapenems.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Bordeaux
• Treatments: Anti-Bacterial Agents; Anti-Infective Agents; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

Criteria

Inclusion Criteria:

• Patient above 18 year-old admitted to intensive care unit

• ESBL-E fecal carriage according to current screening recommendations

• Suspicion of ventilator-associated pneumonia according to ICU society guidelines

Exclusion Criteria:

• Septic shock according to Sepsis-3 classification

• Neutropenia (neutrophils count < 500/mm3)

• Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months.

• Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months

• Treatment with piperacillin-tazobactam in the 10 previous days

• Proven hypersensitivity to penicillin or tazobactam

• Pregnancy or breastfeeding

• Curatorship or guardianship

• Prisoners

• No health insurance